BioAge Labs Presents BGE-102 Clinical Results and Cardiovascular Strategy
BioAge Labs, Inc. (BIOA) held an R&D Day conference call on May 8, 2026, to discuss the clinical progress of its lead program, BGE-102, an oral brain-penetrant NLRP3 inhibitor. Key executives, including CEO Kristen Fortney and Chief Medical Officer Paul Rubin, presented Phase I clinical results and outlined the development strategy for treating cardiovascular and retinal diseases. The event coincided with the company's Q1 2026 earnings report, which revealed an EPS of -$0.52, beating estimates by $0.11, and revenue of $2.77 million, a 91.04% year-over-year increase that surpassed expectations by $1.69 million. The presentation emphasized the therapeutic potential of BGE-102 in targeting inflammation-related conditions. Management provided updates on the drug's safety profile and efficacy data from early-stage trials, aiming to inform investors and analysts about the company's scientific roadmap. The call included a Q&A session with participants such as Matthias Geyer and Michael Davidson, focusing on the strategic implications of the clinical findings and future regulatory steps. This event highlights BioAge Labs' commitment to advancing novel treatments for age-related diseases through targeted inhibition of the NLRP3 inflammasome pathway.
Wire timeline
BioAge Labs Presents BGE-102 Clinical Results and Cardiovascular Strategy
BioAge Labs, Inc. (BIOA) held an R&D Day conference call on May 8, 2026, to discuss the clinical progress of its lead program, BGE-102, an oral brain-penetrant NLRP3 inhibitor. Key executives, including CEO Kristen Fortney and Chief Medical Officer Paul Rubin, presented Phase I clinical results and outlined the development strategy for treating cardiovascular and retinal diseases. The event coincided with the company's Q1 2026 earnings report, which revealed an EPS of -$0.52, beating estimates by $0.11, and revenue of $2.77 million, a 91.04% year-over-year increase that surpassed expectations by $1.69 million. The presentation emphasized the therapeutic potential of BGE-102 in targeting inflammation-related conditions. Management provided updates on the drug's safety profile and efficacy data from early-stage trials, aiming to inform investors and analysts about the company's scientific roadmap. The call included a Q&A session with participants such as Matthias Geyer and Michael Davidson, focusing on the strategic implications of the clinical findings and future regulatory steps. This event highlights BioAge Labs' commitment to advancing novel treatments for age-related diseases through targeted inhibition of the NLRP3 inflammasome pathway.
All Articles on Seeking Alpha